BEIGENE (06160) opened more than 3% higher in early trading. At the time of writing, the stock was up 3.53% to HK$223.2, with a turnover of HK$11.96 million.

On November 17, BEIGENE announced positive results from its Phase III HERIZON-GEA-01 study. The study evaluated the efficacy and safety of zanidatamab, a HER2-targeted bispecific antibody, either as a monotherapy or in combination with the PD-1 inhibitor tislelizumab, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including gastric, gastroesophageal junction, and esophageal cancers.

CSCI previously noted that BEIGENE's zanubrutinib continues to show strong sales growth, prompting an upward revision of its full-year performance guidance. Considering the company's better-than-expected overseas sales of BTK inhibitors, the launch and expansion of PD-1 drugs in markets such as the EU and Japan, and the continued commercialization of key pipelines like BCL-2, BTK CDAC, and CDK4, CSCI maintains its "Buy" rating.